Since the activity of cisplatin in ovarian carcinoma was documented (Wiltshaw & Carr, 1974) it has become the mainstay of most chemotherapeutic regimens (Sessa, 1986) . Controversy remains as to whether platinum-based combinations are superior to cisplatin alone. The only randomised trial to address this question showed a higher response rate for the combination arms (Gruppo Interegion-are Cooperativo Oncologico Ginecologia, 1987) though the dose of single agent cisplatin (50mgm-2) may have been suboptimal in view of the demonstrable dose/response effect in previously treated patients (Ozols et al., 1985) . Nevertheless combination schedules which incorporate cisplatin have become standard in many centres. However, cisplatininduced nausea, vomiting and malaise are often difficult to control and may cause marked morbidity (Wiltshaw & Carr, 1974) . Cumulative renal impairment and peripheral neuropathy occur with significant frequency (Wiltshaw et al., 1986) . These side effects have raised the question whether it is justifiable to treat the majority of women with advanced ovarian cancer with cisplatin-containing regimens (Williams et al., 1985) .
Experience with the platinum analogues has shown that much of this toxicity may be significantly reduced, but myelosuppression is dose limiting (Evans et al., 1983; Bramwell et al., 1985) . In a randomised trial, carboplatin (JM8, CBDCA) as a single agent was as effective as the parent drug in untreated patients with advanced ovarian cancer, but was clearly much better tolerated (Wiltshaw et al., 1985) .
Combinations of carboplatin with alkylating agents are currently being tested. Since increased myelosuppression is inevitable, dose reductions of carboplatin are required, this is rarely necessary when cisplatin is used in combination. It remains to be seen whether such alkylating agent/carboplatin combinations are more effective than carboplatin alone as was seen for the parent drug. This question can only be addressed in a randomised trial, and so this pilot study combining chlorambucil with carboplatin was initiated.
Chlorambucil (CLB) was selected on the basis of minimal toxicity as there is no evidence that one particular alkylating agent is more active than any other in ovarian cancer (Young et al., 1974 The study was designed to determine the dose of CLB which could be safely combined with 300mgm 2 carboplatin.
Patients and methods
Entry into the study was precluded by prior therapy or renal impairment (creatinine clearance <50 ml min -1). Forty-six patients were entered following an initial diagnosis of advanced epithelial ovarian cancer. Though one patient was shown to have a soft tissue sarcoma on pathology review, she is evaluable for toxicity. Characteristics of the other patients are shown in Table I .
Treatment comprised carboplatin 300 mg m 2 as an i.v. infusion in 250ml of 5% dextrose over 30min on day 1. Patients received oral chlorambucil 10mgday-1 for 7, 10 or 14 days on a non-randomised basis. Initially 6 patients were entered at each CLB dose level, but, as the study progressed, all patients were treated on the 7 day schedule. Full blood counts were measured at weekly intervals and in the initial phase of the study subsequent treatment courses were given on day 28 if the WBC >4.0 x 109 1 -1, and platelets > 100 x 109 1 -1. In the later phase of the trial, the threshold WBC for retreatment was reduced to 3.0 x 1091 -1.
Measurable tumour was not a requirement but, where possible, response was evaluated by a second look laparotomy on completion of 6 treatment courses. Complete response (CR) was defined as macroscopic regression of previously documented disease with no evidence of tumour in resected pelvic organs, omentum, random peritoneal biopsies or peritoneal washings. Partial response (PR) was recorded for >50% reduction in tumour volume or microscopic residual disease in resected specimens. Stable disease (SD) comprised a <50% reduction and/or a <25% increase in pretreatment tumour volume: progressive disease was a >25% increase in tumour volume or the appearance of tumour at new sites.
Results

Toxicity
As anticipated, myelosuppression was the major toxicity. Some degree of leucopenia followed the majority of treatment cycles though significant thrombocytopenia was rarely seen until later courses. A falling WBC between days 28 and remaining 3 patients each had a single treatment delay during the 6 courses which were given without dosage modification. Nadir WBC and platelet counts in patients receiving carboplatin with 7 day CLB are shown in Figure 1 . Five of these 29 patients had significant dose reductions for myelosuppression and a further 2 were withdrawn from study due to prolonged leucopenia. Thrombocytopenia was less marked than leucopenia in the early treatment courses, though Figure 1 suggests that bone marrow toxicity may well be cumulative. There was no correlation between nadir WBC and renal function as measured by creatinine clearance. Three patients received oral antibiotics as outpatients for clinical infection. No patient had evidence of spontaneous or tumour related haemorrhage associated with thrombocytopenia. Red cell transfusions were required by 5 patients whose Hb fell to <8gdl-' during treatment, in 2 of these tumour progression was evident. None  3  3  <2cm  12  3  3  1  2  3  2-5cm  12  1  5  2  3  1  >5cm  11  6  2  2  1  Stage IV   7  1  2  1  3   Total  45  5  16  6  10  8 Non-haematological toxicity Treatment was well tolerated by most patients; the majority of courses were administered on an outpatient basis. Some degree of nausea or vomiting (Figure 2 ) was experienced by the majority, despite prophylactic metoclopramide (high dose 11%, standard dose 23% courses), a nabilone/prochlorperazine combination (42% courses), prochlorperazine alone (10% courses) or lorazepam/chlorpromazine (13% courses). The duration of vomiting rarely exceeded 12h and most patients had recovered from nausea by 48 h. One patient developed transient diarrhoea in association with the 5th and 6th carboplatin infusions which was assumed to be drug related.
Renal failure occurred in a single patient during the first cycle. Her creatinine clearance was 78 ml min-1 pretreatment and 23mlmin-i on day 28 without evidence of obstructive uropathy or proteinuria. Therapy continued with CLB alone and renal function recovered spontaneously. In retrospect this was attributed to concomitant therapy with mefanamic acid (Adams et al., 1986 ). Overall 10 of 46 patients received non-steroidal anti-inflammatory drugs at some time during the study (8 mefanamic acid: 2 others) but renal impairment was not seen in the other 9.
Mild alopecia occurred in 3 patients (2 grade I, 1 grade II). One patient experienced transient tinnitus during therapy, without any significant hearing loss on audiometry. Another patient developed lower motor neurone weakness affecting both legs following a combined epidural/general anaesthetic for restaging laparotomy and tumour debulking after 6 treatment cycles. The relative contributions of regional anaesthesia and carboplatin to this complication are unclear. Symptomatic neuropathy did not occur in any of the other 44 patients.
Response
Nine patients are inevaluable for response for reasons noted in Table III . The patient not surgically re-evaluated on grounds of age relapsed with malignant ascites 3 months after chemotherapy was discontinued. The other 3 patients with no residual tumour at the start of treatment remain clinically disease free 6, 9 and 18 months from completion of (Calvert et al., 1982) . In a similar patient population with small cell lung cancer, carboplatin 300mgm2 in combination with VP16-213 resulted in comparable myelotoxicity to the regimen used in this study (Smith et al., 1987) . Our data indicate that 300mgm2 is an appropriate initial dose for patients with ovarian cancer; although a minority will require subsequent dose reduction, dose escalation may be possible.
The 57% response rate is at the lower end of the reported range for platinum-based combination chemotherapy (Sessa, 1986) . It is not clear whether this was in part attributable to suboptimal drug doses, as patient numbers were too low for multivariate analysis. However, there is a correlation between response and extent of residual disease after initial surgery (Gruppo Internationale Cooperativo Oncologico Ginecologia, 1987) and patients with minimal or no residual disease comprised a minority of our patient population (11/ 37 evaluable). The proportion of tumours progressing on chemotherapy was high (10/37); of these 8 had residual disease greater than 2cm at the start of treatment.
The combination was generally well tolerated despite relatively frequent nausea or vomiting. The majority of patients without progressive disease had a Karnofsky Performance status of 100. This represented significant improvement over our prior experience with a cisplatin (50mgm 2 per cycle) containing combination during which prolonged malaise and lethargy were common.
This study confirmed the feasibility and relative nontoxicity of carboplatin and CLB at doses which result in an acceptable response rate. It remains to be seen in the randomised trial whether this combination has any advantage over single agent carboplatin at optimal dose.
